ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards its clinical and development milestones. The results announced by the…

Investors have plenty of exciting updates to look forward as PTX advances clinical trials and its world-leading OmniCAR research platform. Clinical stage oncology company Prescient Therapeutics…

Auspiciously January 2022 will go down as the first month investing for the Merchant Biotech Fund (MBF). I say auspiciously as the Small Ordinaries Index…

New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use of next generation cell therapy platform OmniCAR, which harnesses a…

Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of cancer treatments? The latest research out of the journal Nature…

A new longitudinal study of cancer patients treated with a revolutionary type of cell therapy has shown such promising results that researchers believe it may…

Cancer is one of the significant causes of death worldwide. As per the World Health Organization (WHO), one in six deaths in 2020 were caused…

Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its activity report for the December quarter of the current fiscal…

Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media to discuss the company’s innovative pipeline of personalised cancer therapies….

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the December quarter with a cash balance of $14.77 million, placing it in a strong…